Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

- Robust improvement demonstrated across diverse set of clinical measures -

- Patient-reported outcomes support clinical meaningfulness of improvements in function and strength -

- Meaningful improvements in overall disease burden reported by both patients and physicians -

WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen, formerly known as DYNE-101), in patients with myotonic dystrophy type 1 (DM1) demonstrating clinically meaningful improvements in function and strength at the selected registrational dose. These data are being presented at the 30^th Annual International Congress of the World Muscle Society (WMS), held virtually and in Vienna, Austria, October 7-11, 2025.

“This week we are presenting additional analyses from the data cut shared in June showing that the improvements in function and strength span both the upper and lower limbs, and are clearly meaningful to both patients and physicians,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. “Z-basivarsen was designed to deliver broad functional improvement to patients, and we believe it has the unique potential to mitigate central nervous system-related manifestations of the disease such as cognitive impairment, sleep disturbances and fatigue.”

“I believe the data for z-basivarsen support its potential to bring a wide range of benefits to DM1 patients, helping to improve their ability to function and carry out their daily lives in a way that will really matter to them,” said Valeria Sansone, M.D., Ph.D., Clinical and Scientific Director at the Clinical Center NeMO in Milan, Professor of Neurology, University of Milan, and principal investigator in the ACHIEVE trial. “The consistency of these data across a variety of endpoints out to one-year increases my level of confidence in the potential of z-basivarsen. The patient perception of improvements are encouraging and provide initial evidence that there may be a broad and meaningful effect with z-basivarsen treatment.”